Document is current
Any future updates will be listed below
-
Authors
Duijvelaar, Erik http://orcid.org/0000-0002-5547-5578
Pan, Xiaoke
Bogaard, Harm Jan http://orcid.org/0000-0001-5371-0346
Eringa, Etto C. http://orcid.org/0000-0002-9814-5149
Aman, Jurjan http://orcid.org/0000-0001-6211-1791
-
Funding
Funding for this research was provided by:
AMC foundation
Innovative Medicines Initiative 2 Joint Undertaking (101005142)
ZonMw (10430 01 201 0007)
- License Information
-
More Information
Article History
Received: 8 December 2023
Accepted: 10 February 2024
First Online: 29 February 2024
Declarations
:
: This trial was conducted in compliance with all relevant ethical regulations, including the guidelines of the International Conference on Harmonization Good Clinical Practice and the Declaration of Helsinki. The trial protocol was approved by the medical ethics committee of the Amsterdam UMC (VUmc, Amsterdam, Netherlands) and institutional review board of the Amsterdam UMC, location VUmc. Explicit written informed consent was provided for study participation. Study participants did not receive compensation for their involvement.
: Not applicable.
: Jurjan Aman is a co-inventor of a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). All other authors have no competing interests to declare.
